Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   133 Trials   133 Trials   6479 News 


12345678910111213...7778»
  • ||||||||||  Prolia (denosumab) / Amgen
    Observational data, Retrospective data, Journal:  Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study. (Pubmed Central) -  May 9, 2024   
    Across Spanish PC, we observed a large gap in the treatment and follow-up of elderly subjects experiencing a fragility fracture. Our data highlights the urgent need to improve secondary fracture prevention in PC.
  • ||||||||||  Prolia (denosumab) / Amgen
    Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1652;    
    Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Effect of Denosumab on Mineral and Bone Disorder in Kidney Transplant Recipients: A Preliminary Study (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1644;    
    Our results suggested that Denosumab can reduce the level of bone turnover markers in kidney transplant recipients and has a good safety profile. The long-term effects on bone metabolism and bone mineral density after kidney tranplantation need to be further investigated.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) -  May 6, 2024   
    Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Journal:  3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) -  May 2, 2024   
    3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. (Pubmed Central) -  May 2, 2024   
    Furthermore, a rise in serum TRAP and RANKL levels are detected before markers of bone turnover used in current clinical practice. These mechanistic advances may provide insight into a more defined window of opportunity to intervene with sequential therapy following denosumab discontinuation.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial termination, Metastases:  SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) -  Apr 25, 2024   
    P3,  N=595, Terminated, 
    Completed --> Terminated; Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Retrospective data, Journal:  The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. (Pubmed Central) -  Apr 24, 2024   
    In general, at 2?years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Bone loss after discontinuation of denosumab: the devil is in the details. (Pubmed Central) -  Apr 21, 2024   
    Bone turnover markers were appropriately suppressed and bone mineral density increased in the spine and hip. This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab-induced bone changes in a child: a case report. (Pubmed Central) -  Apr 20, 2024   
    This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications. We present the case of a 9-year-old girl who developed striking bone changes following two years of denosumab therapy for giant cell lesions of the jaw.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review. (Pubmed Central) -  Apr 13, 2024   
    Delayed moderate to severe hypercalcaemia (serum calcium?>?3.0 mmol/l) due to teriparatide is rare but may lead to therapy withdrawal. The underlying predisposing risk factors remain unclear and highlight the importance of a routine serum calcium assessment on therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review. (Pubmed Central) -  Apr 13, 2024   
    Physicians and dentists should provide comprehensive information to patients prescribed with antiresorptive drugs, emphasizing the need for an awareness of the risks of MRONJ in the context of osseointegrated implants. A longer term of follow-up is recommended to identify and manage MRONJ around dental implants in an early manner.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena. (Pubmed Central) -  Apr 6, 2024   
    In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 "relatively new statements" that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw. (Pubmed Central) -  Apr 4, 2024   
    Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction associated with antiresorptive drugs such as bisphosphonates and denosumab...The pre and postoperative density showed no significant correlation to healing behaviour. The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    P3 data, Retrospective data, Journal:  Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. (Pubmed Central) -  Apr 4, 2024   
    P3
    The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction. Data suggest support for the efficacy and safety of continuing romosozumab treatment following fracture.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Giant Cell Tumor of Mandible : A Case Report. (Pubmed Central) -  Apr 3, 2024   
    After exclusion of distant metastasis by F-18 FDG PET scan, she underwent en-bloc resection of the tumor with free fibula flap reconstruction. During 6 months of follow up visit patient had no recurrence.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Recurrent Giant Cell Tumor of Sphenoid Bone: A Rare Finding. (Pubmed Central) -  Apr 3, 2024   
    Here, we describe a case of recurrent giant cell tumor of sphenoid bone in a young male, who underwent surgical resection twice, after which he was advised adjuvant radiotherapy and denosumab. The patient did not take radiotherapy.
  • ||||||||||  Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
    Retrospective data, Journal:  Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy. (Pubmed Central) -  Apr 2, 2024   
    The presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta. (Pubmed Central) -  Mar 30, 2024   
    New therapies are undergoing clinical trials, and it is likely that one or more will receive marketing authorisation within the next three to five years. The long-term outcome from such interventions will need to be studied carefully well beyond the period over which the clinical trials are conducted, and a consistent approach to the collection of data in this regard will be needed as a major collaborative effort.